Stanley T Crooke
CIK 897667 · Exec Chairman of the Board · last filed 2021-01-28
Stanley T Crooke is an Exec Chairman of the Board who has filed 113 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing shows the insider sold $1.8M of IONS on Jan 28, 2021. Across all open-market trades the lifetime net is −$90.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $19.9M across reported positions. 137 SEC filings were submitted jointly with IONIS PHARMACEUTICALS INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IONS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CARLSBAD, CA 92010
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IONS | Exec Chairman of the Board | 496,412 | $40.15 | $19.93M | -$50.31M | 51 | 2021-01-28 |
| IONIS PHARMACEUTICALS INC (ISIS) Delisted | Chairman and CEO | 32,776 | — | — | -$42.81M | 60 | 2015-10-23 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Director | 58,746 | $8.16 | $479.4K | $3.00M | 2 | 2012-11-07 |
Recent Filings
113 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-01-28 | IONS | Sell (S) | −28,333 | -$1.81M | EDGAR |
| 2021-01-25 | IONS | Sell (S) | −75,000 | -$4.61M | EDGAR |
| 2021-01-20 | IONS | Mixed | +31,270 | -$1.25M | EDGAR |
| 2021-01-06 | IONS | Grant (A) | — | $0 | EDGAR |
| 2020-12-17 | IONS | Sell (S) | −40,407 | -$2.01M | EDGAR |
| 2020-12-09 | IONS | Sell (S) | −11,000 | -$568.4K | EDGAR |
| 2020-11-30 | IONS | Mixed | — | -$132.2K | EDGAR |
| 2020-11-25 | IONS | Mixed | — | -$152.2K | EDGAR |
| 2020-09-23 | IONS | Sell (S) | −52,000 | -$2.62M | EDGAR |
| 2020-06-26 | IONS | Sell (S) | −14,914 | -$889.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.